250 related articles for article (PubMed ID: 24434725)
1. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
Game F
Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L; Adler S
Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
[TBL] [Abstract][Full Text] [Related]
3. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
4. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
5. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
6. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):839-57. PubMed ID: 24669954
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
Fang V; Wazny LD; Raymond CB
CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
[No Abstract] [Full Text] [Related]
10. [Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].
Granata A; Insalaco M; Di Nicolò P; Scarfia VR; Russo L; D'anna G; Lentini P; Fiorini F; Fatuzzo P
G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671840
[TBL] [Abstract][Full Text] [Related]
11. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
12. [Antidiabetic Drugs and the Kidney].
Candido R
G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
[No Abstract] [Full Text] [Related]
13. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
14. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
Choby B
FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
[TBL] [Abstract][Full Text] [Related]
15. Achieving glycemic control in patients with type 2 diabetes and renal impairment.
Avogaro A; Schernthaner G
Acta Diabetol; 2013 Jun; 50(3):283-91. PubMed ID: 23212669
[TBL] [Abstract][Full Text] [Related]
16. Review: metformin: potential benefits and use in chronic kidney disease.
Pilmore HL
Nephrology (Carlton); 2010 Jun; 15(4):412-8. PubMed ID: 20609092
[TBL] [Abstract][Full Text] [Related]
17. SGLT-2 inhibition in patients with kidney disease.
Gilbert RE
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S23-7. PubMed ID: 25554068
[TBL] [Abstract][Full Text] [Related]
18. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
19. A review on cardiovascular effects of newer hypoglycaemic medications.
Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
[TBL] [Abstract][Full Text] [Related]
20. Clinical decisions. Glycemic management in a patient with type 2 diabetes.
Hirsch IB; Molitch ME
N Engl J Med; 2013 Oct; 369(14):1370-2. PubMed ID: 24088099
[No Abstract] [Full Text] [Related]
[Next] [New Search]